Professor Mark Dawson

Professor Mark Dawson


Consultant Haematologist and Group Leader
Peter MacCallum Cancer Centre
Elected in 2017
Citation on election

As a clinician-scientist, Professor Dawson has consistently demonstrated academic excellence and leadership both in basic science discoveries and the translation of these findings into the clinical arena. His research into chromatin regulation of normal and malignant haematopoiesis have provided a range of groundbreaking discoveries including the development in collaboration with GSK of the first clinical therapies that target epigenetic reader proteins. This body of work helped establish a new therapeutic paradigm for the treatment of aggressive malignancies. Importantly, he continues to translate these discoveries by leading the multinational clinical trials that have been initiated as a direct consequence of his research.



Find out more

Whether you’re looking to nominate a colleague for an award, make a donation to the Academy or simply find out more about the work we do, research we advance and health policy advice we provide, sign up to our mailing list today.

Keep up to date with the latest news

By providing your email address, you consent to it being added to our mailing list.